Literature DB >> 3198110

Blastomere karyotyping and transfer of chromosomally selected embryos. Implications for the production of specific animal models and human prenatal diagnosis.

C Bacchus1, W Buselmaier.   

Abstract

A method is described that permits the generation of four isolated blastomeres after embryo splitting of murine four-cell eggs and the subsequent chromosomal analysis of one of the obtained 1/4-blastomeres. According to the karyograms obtained, embryos can be selected for reimplantation and furthermore triplicated via the embryo splitting procedure. By employing the described experimental setup, it is possible specifically to produce trisomy 16----2n aggregation chimeras as a postnatal model system of human Down's syndrome. The design can also be used for embryo sexing in stock farming and the selective reproduction of sexed farm animals via embryo transfer. Furthermore the application of blastomere karyotyping in human genetic counseling is discussed for the descendants of carriers of Robertsonian translocations. In addition the reported method could be employed for the genotypic identification of early homozygous embryonic stages from persons carrying frequent recessive mutations. The proposed design could, therefore, widen the spectrum of prenatal diagnosis.

Entities:  

Mesh:

Year:  1988        PMID: 3198110     DOI: 10.1007/bf00273646

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  20 in total

1.  Postimplantation development of blastomeres isolated from 4- and 8-cell mouse eggs.

Authors:  J Rossant
Journal:  J Embryol Exp Morphol       Date:  1976-10

2.  Development of blastomeres of mouse eggs isolated at the 4- and 8-cell stage.

Authors:  A K Tarkowski; J Wróblewska
Journal:  J Embryol Exp Morphol       Date:  1967-08

3.  Research on early human embryos from in-vitro fertilization (IVF): the Warnock recommendations.

Authors:  A McLaren
Journal:  Br J Obstet Gynaecol       Date:  1985-04

4.  Genesis and systematization of cardiovascular anomalies and analysis of skeletal malformations in murine trisomy 16 and 19. Two animal models for human trisomies.

Authors:  C Bacchus; H Sterz; W Buselmaier; S Sahai; H Winking
Journal:  Hum Genet       Date:  1987-09       Impact factor: 4.132

5.  Trisomy 16 in the mouse fetus associated with generalized edema and cardiovascular and urinary tract anomalies.

Authors:  S Miyabara; A Gropp; H Winking
Journal:  Teratology       Date:  1982-06

6.  Morphologic and neurochemical studies of embryonic brain development in murine trisomy 16.

Authors:  H S Singer; M Tiemeyer; J C Hedreen; J Gearhart; J T Coyle
Journal:  Brain Res       Date:  1984-08       Impact factor: 3.252

7.  Neurochemical changes in murine trisomy 16: delay in cholinergic and catecholaminergic systems.

Authors:  P T Ozand; R L Hawkins; R M Collins; W D Reed; P J Baab; M L Oster-Granite
Journal:  J Neurochem       Date:  1984-08       Impact factor: 5.372

8.  Conserved chromosomal positions of dual domains of the ets protooncogene in cats, mice, and humans.

Authors:  D K Watson; M J McWilliams-Smith; C Kozak; R Reeves; J Gearhart; M F Nunn; W Nash; J R Fowle; P Duesberg; T S Papas
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

9.  Genes coding for sensitivity to interferon (IfRec) and soluble superoxide dismutase (SOD-1) are linked in mouse and man and map to mouse chromosome 16.

Authors:  D R Cox; L B Epstein; C J Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

Review 10.  Genetic basis for a mouse model of Down syndrome.

Authors:  R H Reeves; J D Gearhart; J W Littlefield
Journal:  Brain Res Bull       Date:  1986-06       Impact factor: 4.077

View more
  1 in total

1.  Investigation of effects of pregnant mare serum gonadotropin (PMSG) on the chromosomal complement of CD-1 mouse embryos.

Authors:  S Ma; D K Kalousek; B H Yuen; Y S Moon
Journal:  J Assist Reprod Genet       Date:  1997-03       Impact factor: 3.412

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.